Company intelligence / Profile preview

Commense

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Commense specializes in defined microbiome therapeutics for pediatric and maternal health, including preclinical development of a live biotherapeutic (FLVR: Faecalibacterium, Lachnospira, Veillonella, Rothia) for prevention of childhood asthma and other allergic diseases. Preclinical models show reduced respiratory disease signs with FLVR administration; human clinical trials were anticipated but results are not yet reported.

Therapeutic areas: ImmunologyPulmonology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Partnerships

University of British Columbia (licensing of microbiome therapeutic)Collaboration with academic experts including co-founder B. Brett Finlay, Ph.D.Affiliation with PureTech Health and leverage of expertise from Vedanta Biosciences

Beyond the preview

Go deeper on Commense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Commense.

Explore the full profile